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Computer-aided drug design is among the most valuable tools we have in order to design new 
drug molecules. Herein, with the aid of the Drug Design Workshop platform, we describe our 
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The COX isozymes 
 
Cyclooxygenase, also known as COX, is a family of enzymes consisting of two isoforms, 
COX-1 and COX-2, which are responsible for the production of prostaglandins, chemical 
messengers that regulate certain body functions and are known to cause inflammation. The 
first isoform, COX-1, plays a vital role in the gastric mucosal defense against gastric acids as 
well as ensures normal kidney and platelet function. Thus, it can be located in parts of the 
body such as the stomach and the kidneys. On the other hand, COX-2 is responsible for 
catalyzing the production of prostaglandins and can be located in immune cells, endothelial 
cells of blood vessels as well as synovial fibroblasts, which are associated with the 
development of inflammation.   
 
Non-steroidal anti-inflammatory drugs (NSAIDs) 
 
Non-steroidal anti-inflammatory drugs (NSAIDs)1 are a category of drugs which target the COX 
isoforms and can be categorized as selective and non-selective NSAIDs. The selective NSAIDs 
target only the COX-2 isoform without affecting COX-1, thus minimizing chances of gastric 
hemorrhage, peptic ulcer and cardiovascular diseases. In contrast, non-selective drugs bind 
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to both isoforms, thus inhibiting inflammation but at the same time reducing the beneficial 
functions of COX-1. 
 
A typical example of a non-selective NSAID is ibuprofen. It has anti-inflammatory, antipyretic 
and analgesic effects. While it can aid the prevention of inflammations, it is also connected 
with causing gastric side effects, although milder than other NSAIDs. 
 
One of the most prominent selective NSAIDs is celecoxib, which has anti-inflammatory effects 
and is used in order to reduce fever as well as arthritic pain. It functions through an enhanced 
binding to COX-2 as compared to COX-1. Within the two target isozymes there are two 
potential binding pockets. The active site and the “neighboring” allosteric site. In this area 
COX-1 and COX-2 differ by one amino acid. More specifically, instead of isoleucine (Ile) in COX-
1 there is valine (Val) in COX-2. However, due to the larger size of isoleucine as compared to 
valine, the entry of celecoxib into the allosteric pocket of COX-1 becomes difficult. Therefore, 
celecoxib is more strongly bound to the COX-2 isozyme. Thus, celecoxib meets the criteria of 
a good drug, as it binds strongly to the target protein, reducing prostaglandin production, 
while its weaker interaction to COX-1 does not cause significant side effects. The drug, 
commercially known as Celebrex, is currently the only available inhibitor of COX-2. On the 
other hand, the non-selective ibuprofen, which is a smaller molecule that celecoxib, binds only 
to the active site. In Figure 1 the relative LigPlot diagrams2,3 are depicted, while in Figure 2 












Figure 2: Interaction of celecoxib with COX1 (left) and COX2 (right). 
 
 
Computer-aided drug design 
 
In recent years, new methods have been developed for designing new drugs by using a 
computer. Thanks to them, the cost and time of discovering a new medicine that will be 
released on the market is reduced. More specifically, the branch of computational chemistry 
that deals with the above purpose is called Computer-Aided Drug Design (C.A.D.D.). 
Computational drug design can be approached in two ways, to date: computer-based 
macromolecular design (structure-based drug design) and computational design based on the 
substitute-binder (ligand-based drug design). 
 
In computational design based on the macromolecule-target, the three-dimensional 
macromolecular structure (proteins or RNA) is studied, in order to identify the points where 
the biological function under investigation is performed. An effective drug can be designed 
based on these observations. One method is to find the compound from large databases with 
small molecules that is suitable for the macromolecule binding point using docking software. 
In addition, the structure of an existing drug can be improved / redesigned to bind to the 
macromolecule and meet the pharmacokinetic criteria of a drug (Lipinski's Rules)6. The 
improvement of the lead molecule becomes in terms of enhancing its affinity to target’s 
binding sites in multiple trial-and-error cycles. 
 
On the other hand, in computational design based on a well-known substitute-binder, the 
relationship between the structure and properties of the substitute and its biological function 
is examined (quantitative structure-activity relationships). Taking advantage of this 
relationship, existing drugs can be improved, or even more effective compounds can be 
redesigned. For example, if the substitute comes from nature, it is necessary to first locate 
the pharmacophore, that part of the compound that includes the groups responsible for the 
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activity and to isolate it from the other substances in the natural product. Then, with a 
methodical chemical modification of the lead compound and screening of the new possible 
drugs, the process of finding the most suitable drug proceeds. 
In our work we employ the Drug Design Workshop platform7, developed by the Swiss Institute 
of Bioinformatics. The platform is set out to introduce computational chemistry and more 
accurately computational drug design to the public. It provides the opportunity to examine 
the interaction between an existing drug or an entire new molecule with a target-protein 
(COX-1, COX-2, BRAF V600E, BRAF wt, IDO1). In doing so, the docking of the ligand to the 
protein-target is taking place in real time in order to provide a variety of data concerning this 
inhibition, such as the score value which represents the stability of the inhibition, the 
probabilities of the ligand inhibiting different substrates and also several pharmacokinetic 
data concerning this ligand. 
 
Designing non-steroidal anti-inflammatory drugs in the Drug Design Workshop 
platform  
 
The objective of this research is to employ basic docking techniques, as they are provided by 
the publicly available Drug Design Workshop platform, in order to design a molecule with a 
high affinity to the COX-2 pocket and a low affinity to the relative isoenzyme. Within this 
framework the drug molecule should inhibit the target-protein, while the side effects due to 
the COX-1 isoform should be reduced. Moreover, pharmacokinetic data, as provided by the 
SwissADME8 prediction tool, are used to support our docking experiments. 
Several candidate molecules have been tested starting from the celecoxib as the lead 
compound. We followed a systematic change pathway in celecoxib’s initial structure adding 
and subtracting electrophilic and nucleophilic groups to the main chain. From this extended 
trial-and-error approach ten compounds have been selected. These compounds show high 
affinity to the COX-2 pocket along with high selectivity towards the target isozyme. The 
resulting candidate drug molecules along with their predicted properties are depicted in 
Tables 1 and 2. 
 










































Table 2: Predicted properties of 1-10. 
Molecule 
Substrate with 
higher probability of 
inhibition* 







100% towards COX2 
82% towards COX1 
 
high molecular 
weight, too lipophilic 
2 
100% towards COX2 
90% towards COX1 
 
high molecular 
weight, too lipophilic 
3 
80% towards COX2 




weight, too lipophilic 
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4 
98% towards COX2 
50% towards COX1 
 
high molecular 
weight, too lipophilic 
5 
75% towards COX2 




45% towards COX2 
25% towards COX1 
 
high molecular weight 
7 
45% towards COX2 
20% towards COX1 
 
 
high molecular weight 
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8 
20% towards COX2 




weight, too lipophilic 
9 
40% towards COX2 
15% towards COX1 
 
 
high molecular weight 
10 
10% towards COX2 




weight, too lipophilic 
* Through a combination of 2D and 3D similarity with a library of 370000 known actives 
on more than 3000 proteins from three different species there were found the most probable 
macromolecular targets for the molecule. 
** LIPO: Lipophilicity, POLAR: Polarity, INSOLU: Insolubility, INSATU: Insaturation and 
FLEX: Flexibility 
 
Among compounds 1-10, the most promising one was found to be 2 (Figure 3). It shows a high 
score (12.6) and high drug likeness. Furthermore, it's highly probable it can be administered 
per se as it has almost all the suitable physicochemical properties for oral bioavailability. 
However, there are certain downsides. The compound in question has high molecular weight 
and is too lipophilic, thus it is not expected to show very favorable ADMET properties, 
especially towards absorption and distribution.  




Figure 3: Pharmacokinetic data of the compound 2 from the SwissADME platform (up), interaction of the compound 2 with 
COX2 (down left) from the Drug Design Workshop platform and score value of the compound 2 (down right) from the Drug 




Herein we report the design of a new non-steroidal anti-inflammatory drug which is 
anticipated to own high selectivity upon the target isozyme COX-2. In order to achieve our 
goal, we employed celecoxib as the lead compound and in several steps, we modified its 
structure testing new compounds’ potential activity with the docking platform Drug Design 
Workshop. We found that with a slight modification in the parent structure, i.e., the addition 
of a m-methyl group, an enhancement of the target-drug affinity can be achieved, without a 
significant change to druglikeness to be occurred. 
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